Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 4/20 | 0.55 |
| ▸ | EIF4A3 | P38919 | 12/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMO | Q99835 | 1/20 | 0.45 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11957919 | 0.94 | MDM2 (0.56) | MDM2EIF4A3 | |
| SCHEMBL11957955 | 0.94 | EIF4A3 (0.53) | MDM2EIF4A3SMOMGLL | |
| SCHEMBL11957943 | 0.92 | MDM2 (0.55) | MDM2EIF4A3ALDH1A1LMNAMGLL | |
| SCHEMBL11957973 | 0.91 | MDM2 (0.50) | MDM2EIF4A3MGLL | |
| SCHEMBL11958366 | 0.91 | MDM2 (0.50) | MDM2EIF4A3MGLL | |
| SCHEMBL11958395 | 0.90 | MDM2 (0.52) | MDM2EIF4A3MGLL | |
| SCHEMBL11957953 | 0.90 | MDM2 (0.53) | MDM2EIF4A3 | |
| SCHEMBL11957970 | 0.89 | MGLL (0.59) | MDM2EIF4A3ALDH1A1LMNAMGLL | |
| SCHEMBL11958448 | 0.89 | MDM2 (0.53) | MDM2EIF4A3 | |
| SCHEMBL11958547 | 0.89 | MDM2 (0.52) | MDM2EIF4A3MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130072468-A1 | SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS | GILBERT ERIC J (US) | 2013-03-21 | — | — | US | disclosed |
| US-8236805-B2 | Substituted piperazines as CB1 antagonists | INTERVET INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-8236805-B2 | Substituted piperazines as CB1 antagonists | INTERVET INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-7700597-B2 | Substituted piperazines as CB1 antagonists | SCHERING CORPORATION (US) | 2010-04-20 | — | — | US | disclosed |
| US-7700597-B2 | Substituted piperazines as CB1 antagonists | SCHERING CORPORATION (US) | 2010-04-20 | — | — | US | disclosed |
| US-20100029607-A1 | Substituted Piperazines as CB1 Antagonists | SCHERING CORPORATION | 2010-02-04 | — | — | US | disclosed |
| US-20100029607-A1 | Substituted Piperazines as CB1 Antagonists | SCHERING CORPORATION | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072468-A1 | SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS | CNR1, CNR2, GPR119 | MDM2 4116/4885EIF4A3 3965/4885ALDH1A1 1520/4885 |
| US-20100029607-A1 | Substituted Piperazines as CB1 Antagonists | CNR1, CNR2, GPR119 | MDM2 4116/4885EIF4A3 3965/4885ALDH1A1 1520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.